{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T00:18:37Z","timestamp":1758845917779,"version":"3.44.0"},"reference-count":10,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T00:00:00Z","timestamp":1757462400000},"content-version":"vor","delay-in-days":12,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Merck Sharp & Dohme LLC"},{"DOI":"10.13039\/100004334","name":"Merck & Co., Inc.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,8,29]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>We adapted a previous discrete event simulation model to assess the impact of varying time distributions from disease-causal human papillomavirus (HPV) infection to CIN2+ onset on the estimated age distribution of disease-casual infection in the United States. Differences in these assumptions had minimal effect on estimates, underscoring the importance of expanded HPV vaccination.<\/jats:p>","DOI":"10.1093\/ofid\/ofaf548","type":"journal-article","created":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T09:10:34Z","timestamp":1757495434000},"source":"Crossref","is-referenced-by-count":0,"title":["Assessing the Impact of Methodological Assumptions on Estimated Age of Disease-Causal Human Papillomavirus Infection in US Females"],"prefix":"10.1093","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8654-2772","authenticated-orcid":false,"given":"Alhaji","family":"Cherif","sequence":"first","affiliation":[{"name":"Biostatistics and Research Decision Sciences (BARDS), Merck & Co., Inc. , Rahway, New Jersey ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuedan","family":"You","sequence":"additional","affiliation":[{"name":"Value and Implementation (V&I), Merck & Co., Inc. , Rahway, New Jersey ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8758-8326","authenticated-orcid":false,"given":"John","family":"Cook","sequence":"additional","affiliation":[{"name":"Modeling and Adaptation, CHEORS , Chalfont, Pennsylvania ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miriam","family":"Reuschenbach","sequence":"additional","affiliation":[{"name":"Global Medical & Scientific Affairs, MSD Sharp & Dohme GmbH , Munich ,","place":["Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ya-Ting","family":"Chen","sequence":"additional","affiliation":[{"name":"Value and Implementation (V&I), Merck & Co., Inc. , Rahway, New Jersey ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5852-9770","authenticated-orcid":false,"given":"Craig","family":"Roberts","sequence":"additional","affiliation":[{"name":"Value and Implementation (V&I), Merck & Co., Inc. , Rahway, New Jersey ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruifeng","family":"Xu","sequence":"additional","affiliation":[{"name":"Biostatistics and Research Decision Sciences (BARDS), Merck & Co., Inc. , Rahway, New Jersey ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,9,10]]},"reference":[{"key":"2025092508531808400_ofaf548-B1","doi-asserted-by":"crossref","first-page":"724","DOI":"10.15585\/mmwr.mm6833a3","article-title":"Human papillomavirus-attributable cancers\u2014United States, 2012\u20132016","volume":"68","author":"Senkomago","year":"2019","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2025092508531808400_ofaf548-B2","doi-asserted-by":"crossref","first-page":"918","DOI":"10.15585\/mmwr.mm6733a2","article-title":"Trends in human papillomavirus-associated cancers\u2014United States, 1999\u20132015","volume":"67","author":"Van Dyne","year":"2018","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2025092508531808400_ofaf548-B3","doi-asserted-by":"crossref","first-page":"698","DOI":"10.15585\/mmwr.mm6832a3","article-title":"Human papillomavirus vaccination for adults: updated recommendations of the advisory committee on immunization practices","volume":"68","author":"Meites","year":"2019","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2025092508531808400_ofaf548-B4","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1093\/jnci\/djz227","article-title":"Estimating the natural history of cervical carcinogenesis using simulation models: a CISNET comparative analysis","volume":"112","author":"Burger","year":"2020","journal-title":"J Natl Cancer Inst"},{"key":"2025092508531808400_ofaf548-B5","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofab111","article-title":"Median age at HPV infection among women in the United States: a model-based analysis informed by real-world data","volume":"8","author":"Prabhu","year":"2021","journal-title":"Open Forum Infect Dis"},{"key":"2025092508531808400_ofaf548-B6","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1158\/1055-9965.EPI-10-0791","article-title":"Incident cervical HPV infections in young women: transition probabilities for CIN and infection clearance","volume":"20","author":"Insinga","year":"2011","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"2025092508531808400_ofaf548-B7","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1002\/ijc.29971","article-title":"Progression of HPV infection to detectable cervical lesions or clearance in adult women: analysis of the control arm of the VIVIANE study","volume":"138","author":"Skinner","year":"2016","journal-title":"Int J Cancer"},{"key":"2025092508531808400_ofaf548-B8","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1158\/1055-9965.EPI-13-0973","article-title":"A population-based evaluation of cervical screening in the United States: 2008\u20132011","volume":"23","author":"Cuzick","year":"2014","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"author":"US Department of Health and Human Services","key":"2025092508531808400_ofaf548-B9"},{"key":"2025092508531808400_ofaf548-B10","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1080\/17477778.2018.1442155","article-title":"Strengthening the reporting of empirical simulation studies: introducing the STRESS guidelines","volume":"13","author":"Monks","year":"2019","journal-title":"J Simul"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ofid\/advance-article-pdf\/doi\/10.1093\/ofid\/ofaf548\/64234920\/ofaf548.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/12\/9\/ofaf548\/64234920\/ofaf548.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/12\/9\/ofaf548\/64234920\/ofaf548.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T12:53:22Z","timestamp":1758804802000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofaf548\/8250428"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,29]]},"references-count":10,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,8,29]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofaf548","relation":{},"ISSN":["2328-8957"],"issn-type":[{"type":"electronic","value":"2328-8957"}],"subject":[],"published-other":{"date-parts":[[2025,9]]},"published":{"date-parts":[[2025,8,29]]},"article-number":"ofaf548"}}